SITC Poster 527: Advance Immunotherapy Development with a Tumor Organoid/Immune Cell Co-Culture System
Tumor Organoid and Immune Cell Co-Culture System Potentiates Immuno-Oncology Drug Development
Hongjuan Zhang, Jun Zhou, Shuang Zhu, Jia Zheng, Limei Shang, Chunmei Li, Xuefei Yan, Rui Zhang, Mingfa Zang, Annie An, Xiaoxi Xu, Shuzong Wang, Henry Li, and Yujun Huang
New patient-derived models such as organoids are revolutionizing in vitro drug development; however, challenges still remain in modeling the tumor microenvironment (TME) in vitro. We’ve developed a co-culture system which reconstitutes components of the TME, through the combination of tumor organoids and various immune cells in vitro.
This poster details the establishment of the co-culture platform, and the assessment of the immune modulatory and tumor killing effects of immuno-oncology drug candidates including CAR-T cell therapies.
Read this Poster to Discover:
- That co-culture of tumor organoids with allogenic T cells from healthy donors is used to assess immune checkpoint blockade
- How tumor organoids are profiled for tumor associated antigen expression and used to evaluate tumor killing assays for bi-specific T cell engagers and CAR-T cells
- How the profiling data of immune checkpoint targets of interest in our banked organoids provides comprehensive information for model selection in preclinical testing of I/O drugs
Download the Poster Now!